Blog

Reflecting on Three Months of Lockdown

As we start to come out of lockdown with our own “4th July” in the UK, I’ve been reflecting on the last three months. Unless you had a critical job to perform, you were to stay at home and only leave to get necessary groceries or exercise. While W2O had a work from home policy …

Location, Location, Location: Why the European Medicines Agency Move from London to Amsterdam is Important for Medicine

Big news this week in the pharma world was the decision on where the medicine regulatory body the European Medicines Agency (EMA) will move to, when it decamps from its London base to Amsterdam, due to Brexit. The EMA is a key body in Europe for the evaluation and approval of new medicines for both …

We Need to Talk About Pharma –– How Do We Get Society to Rethink its Position on the Healthcare and Life sciences Industry?

As representatives of healthcare and life sciences industry, in the broadest sense, we spend a lot of time talking between ourselves about our relevance and value to society. We know what this is. To us, as a market, it is obvious. So why does no one want to talk to us about it? Don’t they …

AI, Europe, and the New Customer Experience

From ubiquitous technologies to data privacy to multi-platform convenience, Europeans are on the verge of redefining how consumers and brands interact Artificial Intelligence (AI) is quickly becoming more and more accepted not only in our personal lives but for business as well. It seems like each day we are exposed to a different AI application …

Brexit: Sitting with the Discomfort to Define the Opportunity

With the uncertainty brought about by the Brexit vote, Pharma and Biotech companies need to consider a number of unique opportunities to chart future growth in the UK and EU On 23 June 2016 the UK government held a referendum on either exiting or remaining a part of the EU and 52% of voters opted to leave …

Say “hi.”

Contact Us